NfL has already served as an endpoint in clinical trials; for example, in multiple sclerosis, a dynamical decrease of CSF NfL was observed in clinical trials with Fingolimod [49] and a reduction of blood NfL has been documented in clinical trials with Tofersen in ALS patients [50]. The gene discussed is NEFL; the disease is multiple sclerosis.